- SID Mtg
Society for Investigative Dermatology | Dermatology Research | Academic Dermatology
|Sun Pharma Awards|
Sun Pharma/SID Mid-Career Awards
Congratulations to the 2019 Sun Pharma/SID Mid-Career Award Recipients!
Dawn Siegel, MD, Medical College of Wisconsin
My research focuses on the discovery of the genetic basis of hemangioma syndromes associated with congenital malformations. In 2006, I founded the PHACE Syndrome International Clinical Registry and Genetic Repository. PHACE is an acronym for Posterior Fossa Anomalies, Hemangiomas, Arterial Anomalies, Cardiac Defects, Eye Anomalies and Sternal Anomalies. In 2013, I was awarded an R01 entitled “Pathogenesis & Natural History in a Longitudinal Hemangioma Syndrome Cohort.” Through this award, I made significant progress in understanding the natural history of PHACE syndrome and generated preliminary data to investigate the genetic basis of PHACE. I have an established DNA and tissue bank for this cohort. I was awarded a Gabriella Miller Kids First X01 for whole genome sequencing of 100 families. Characterization of genomic alterations in PHACE will lead to better understanding of the pathobiology and subsequently identify predictive factors for long-term morbidity. We will generate fundamental information regarding the pathogenesis of PHACE, which will ultimately uncover new gene targets and pathways that can be used in the development of therapies for infantile hemangioma.
Suzanne Cassel, MD, Cedars-Sinai
Currently, the majority of our understanding of innate immune receptors is related to responses to infectious stimuli. While our group has established a role of the NLR family of innate immune receptors in sterile inflammatory responses, my future studies aim to focus on the innate immune response to malignancy, including melanoma. This interaction is remarkably complex, with the tumor at times benefiting from inflammatory responses and at other times being damaged by immune responses. It is also two-way, with the melanoma cells modulating the innate immune cells’ ability to respond to stimuli as well as the innate immune cells having effects directly and indirectly on the melanoma. My long-term career goal is to delineate the complex relationship of innate pattern recognition receptors with melanoma tumorigenesis and progression, and in particular to unharness the specific and directed adaptive immune response against melanoma.
Sun Pharma/SID Mid-Career Investigator Awards are intended to bridge funding gaps for outstanding mid-career investigative dermatologists.
Based on a generous gift from Sun Pharma, and supplemented by the SID, there will be up to five Bridge Awards of $100,000 each given in 2019 to deserving mid-career investigators in the field of dermatology or cutaneous biology.
Active SID Members who are an MD, DO, PhD, MD/PhD or equivalent, and holding a full-time faculty position at a US Department or Division of Dermatology or equivalent.
An independent SID Grant Review Committee will select award recipients.
For further information or questions please contact Becky Minnillo